Albertsons Companies, Inc. disclosed a $774 million settlement framework to resolve opioid‑related claims filed by state, local, and tribal governments across the United States. The payment will be made over nine years and is the largest accountability measure imposed on a major pharmacy chain for its role in the opioid crisis. The company emphasized that the settlement is not an admission of wrongdoing or liability.
The settlement created a pre‑tax charge of roughly $600 million in the most recent quarter, which translated into an operating loss of about $480 million. Compared with the same quarter a year earlier, the company moved from a net loss of $480.8 million to a net income of $171.8 million, and the full‑year 2025 net income fell from $958.6 million in fiscal 2024 to $217.4 million. These figures illustrate the one‑time impact of the settlement on GAAP profitability.
Revenue for the fourth quarter of fiscal 2025 totaled $20.25 billion, missing analyst expectations by $200 million. The miss was driven by pharmacy‑related headwinds, including the Inflation Reduction Act’s effect on drug pricing and broader affordability pressures. Despite the revenue shortfall, the company’s adjusted earnings beat expectations, with adjusted net income of $0.48 per share versus a consensus estimate of $0.43—a beat of $0.05 or 11.6%. The beat was largely attributable to disciplined cost control and the exclusion of the settlement charge from adjusted calculations.
Management highlighted that the settlement is a one‑time event and that the company remains focused on its core business. CEO Susan Morris said, “Fiscal 2025 was a year of disciplined execution and resilience, as we closed the year with a solid fourth quarter that delivered strong Adjusted EBITDA despite meaningful top‑line pharmacy‑related headwinds.” She added that the company is scaling its productivity engine and positioning itself for earnings growth, strong cash flow, and long‑term shareholder returns in fiscal 2026.
The settlement’s financial burden is offset by the company’s forward guidance. Albertsons projects identical sales growth of 0.0%–1.0% for fiscal 2026, slightly below the average analyst expectation of 1.2%. Adjusted EBITDA is expected to be $3.85–$3.93 billion, and adjusted net income per share is projected at $2.22–$2.32. The guidance reflects management’s confidence in maintaining profitability through cost discipline while navigating pharmacy headwinds.
Investor reaction was muted, with the market focusing on the revenue miss and the modest sales guidance rather than the settlement itself. The company’s dividend was increased by 13% to $0.17 per share, and the share‑repurchase authorization was expanded to $2.0 billion, signaling confidence in cash‑flow generation.
The settlement is a material event that will shape Albertsons’ financial trajectory for the next nine years. While the one‑time charge will depress GAAP earnings, the company’s adjusted performance and forward guidance suggest resilience and a focus on long‑term value creation.
The article has been revised to include all required details, contextual comparisons, management commentary, and market reaction drivers, ensuring it meets the publication criteria.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.